ADMA Biologics, Inc. ADMA
Updated: 12 Sep 2026
No signal published yet
We already track ADMA Biologics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow ADMA Biologics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ADMA Biologics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, ADMA Biologics reported its second-quarter 2026 financial results, generating $124.4 million in total revenue and $37.8 million in net income. Revenue growth was primarily driven by flagship product ASCENIV, which rose 24% year-over-year to $102.9 million.
What Firelda Watch includes for ADMA Biologics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow ADMA Biologics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ADMA Biologics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more